The webinar’s topic will focus on how misaligned market incentives and misinformation discourage the use of lower-priced alternatives such as Join us for a panel discussion focused on how misaligned market incentives and misinformation discourage the use of lower-priced alternatives such as biosimilars and what policy and educational solutions may encourage uptake of this new class of medicines.
Biosimilars represent at once a breakthrough innovation on behalf of patients and a gateway solution that can address the challenges of cost and access. That’s why our webinar will focus on the extraordinary potential of these medicines, as well as how misaligned market incentives and misinformation discourage the use of this and other lower-priced alternatives. We will also explore the policy and educational choices that can encourage new and expanded utilization — and take permanent strides towards a biosimilar future.
Dr. Robert Popovian, Pharm.D., MS – Moderator
Dr. Robert Popovian is a healthcare and biopharmaceutical Leader accomplished in pharmaceutical science, business and government, with a distinctive array of academic and practical experience across a wide range of healthcare and business management functions. Positioned at the intersection of economics, policy, and innovation which maximizes patient access, Dr. Popovian fosters an environment of performance, leadership, inclusiveness and innovation. In fact, he is one of the few experts who has studied and published both clinical and policy related economic analysis as well as one of a handful who have studied and published empirical data regarding emerging payment mechanisms in the US healthcare system. He is also one of the first to secure inclusion of health outcomes data regarding labeled indication of a biopharmaceutical.
Peter Pitts – Panelist
Peter Pitts is President of the Center for Medicine in the Public Interest and Chief Regulatory Officer at Adherent Health Strategies. A former member of the United States Senior Executive Service, Peter was FDA’s Associate Commissioner for External Relations, serving as senior communications and policy adviser to the Commissioner. He supervised FDA’s Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug taskforce and is a Special Government Employee (SGE) consultant to the FDA’s Risk Communications Advisory Committee. He is also a Adjunct Scholar at the Washington Policy Center.
Dr. Wayne Winegarden, PhD – Panelist
Wayne Winegarden, Ph.D., is a Sr. Fellow in Business & Economics, Pacific Research Institute, as well as the Director of PRI’s Center for Medical Economics and Innovation. Dr. Winegarden’s policy research explores the connection between macroeconomic policies and economic outcomes, with a focus on fiscal policy, the health care industry, and the energy sector. As Director of the Center for Medical Economics and Innovation, Dr. Winegarden spearheads research and advances policies that support the continued viability and vitality of the U.S. biomedical and pharmaceutical industries to the benefit of patients and overall economic growth.
Terry Wilcox – Panelist
A passionate advocate for patients with cancer and other serious diseases, Terry Wilcox is Executive Director of Patients Rising, a non-profit patient education and advocacy organization that helps patients get access to essential diagnostics and the treatments they need. Inspired by Selma Schimmel, considered by many as the “original” young adult survivor advocate, Terry left a career in Los Angeles in the entertainment industry to join Vital Options International (VOI), a cancer communication, education and advocacy organization Selma launched in 1983 to facilitate a global dialogue on cancer. In August 2015, Terry co-founded Patients Rising, where she and her team engage the patient community, along with physicians, health policy experts and allied healthcare professions, to develop realistic, solution-oriented discussions so those with life-threatening and chronic diseases will have a voice in shaping policies that will improve access to quality care.